Orphazyme to present at the Gordon Research Conference on Lysosomal Diseases 14.-19. April in Tuscany.
Thomas Kirkegaard, CSO, will present results from animal pharmacological models of the company’s lead program and clinical development plans for the company’s potential pan-LSD therapy, a recombinant version of HSP70, at the prestigious Gordon Research Conference on Lysosomal Diseases, taking place in Tuscany, Italy on 14.-19. April.
“We are proud to present our latest results that offer important new insights into the potential of our lead clinical program”, says CSO Thomas Kirkegaard. “The rapid progression of our lead program underscores our commitment to advancing our understanding of the lysosomal storage diseases and their treatment, as well as our dedication to bring a novel therapeutic opportunity to people living with these devastating diseases.”
Aside from the presentation by company CSO, Thomas Kirkegaard, data on the potential of HSP70 will also be presented in a poster by scientist James Gray from the group of Professor Frances Platt at Oxford University.